Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.

NCT02841748 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02841748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02841748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2017
Completion date
October 23, 2025
Enrollment
100 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, squamous cell carcinoma of the head and neck